Holen Sie sich die Stockscreener-App
1.18
4.84%
-0.06
Schlusskurs vom Vortag:
$1.24
Offen:
$1.22
24-Stunden-Volumen:
109.28K
Relative Volume:
0.11
Marktkapitalisierung:
$112.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.31M
KGV:
-4.4612
EPS:
-0.2645
Netto-Cashflow:
$-21.07M
1W Leistung:
-5.60%
1M Leistung:
+85.24%
6M Leistung:
+45.79%
1J Leistung:
+15.69%
1-Tages-Spanne:
$1.12
$1.24
1-Wochen-Bereich:
$1.12
$1.35
52-Wochen-Spanne:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ONCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.1899 | 109.16M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.33 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.47 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.46 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
Oncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL Event - TipRanks
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential – Company AnnouncementFT.com - Financial Times
Cancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025 - Baystreet.ca
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
What analysts say about Oncolytics Biotech Inc. stockTremendous growth opportunities - Autocar Professional
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
What drives Oncolytics Biotech Inc. stock priceDynamic profit expansion - Autocar Professional
Oncolytics Biotech Inc. Stock Analysis and ForecastFree Investment Case Studies - jammulinksnews.com
Pancreas Cancer Becoming Top Focus for Biotech Co.? - streetwisereports.com
Oncolytics Biotech Regains Compliance With Nasdaq's Minimum Bid Price Rule - 富途牛牛
Oncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025 - TipRanks
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules - The Globe and Mail
Oncolytics Biotech regains compliance with Nasdaq listing requirements - Investing.com
Oncolytics regains Nasdaq compliance - TipRanks
Oncolytics Biotech® Regains Compliance With Nasdaq Trading Rules - Barchart.com
Is Oncolytics Biotech Inc. a good long term investmentHigh-yield portfolio picks - jammulinksnews.com
How To Trade (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics names Jared Kelly as CEO - MSN
Oncolytics Biotech (ONCY) up more than 100% since Jun 23 - AInvest
What makes Oncolytics Biotech Inc. stock price move sharplyAnalyst Grade Signals - beatles.ru
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Cantech Letter
Emerging Oncology Breakthroughs Signal Opportunity Despite Research Funding Crunch - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Unveils Promising Data on Pelareorep’s Efficacy Across Tumor Types - TipRanks
Oncolytics Biotech reports positive biomarker data for pelareorep - Investing.com
Oncolytics Biotech reports positive biomarker data for pelareorep By Investing.com - Investing.com South Africa
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types - Barchart.com
(ONC) Trading Strategy and Analysis (ONC:CA) - news.stocktradersdaily.com
How the (ONC) price action is used to our Advantage (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech Highlights Promising Pelareorep Data in Cancer Treatment - TipRanks
Oncolytics Biotech stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Cantech Letter
Next-Gen Cancer Treatments Gain Steam Amid Oncology Industry Shakeups - Baystreet.ca
USA News Group: Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - FinanzNachrichten.de
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.50%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):